| |
| |
|
| Insider
Information: |
Hohl Benjamin |
| Relationship: |
|
| City: |
Boulder |
| State: |
CO |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
0 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Enliven Therapeutics Ord Shs |
ELVN |
|
2024-05-03 |
0 |
2023-12-22 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
22 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-05-03 |
4 |
AS |
$22.50 |
$22,500 |
D/D |
(1,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-05-03 |
4 |
OE |
$2.48 |
$2,480 |
D/D |
1,000 |
1,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-29 |
4 |
AS |
$16.97 |
$55,165 |
D/D |
(3,250) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-29 |
4 |
OE |
$2.48 |
$8,060 |
D/D |
3,250 |
3,250 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-11 |
4 |
OE |
$2.48 |
$34,720 |
D/D |
14,000 |
14,000 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-11 |
4 |
AS |
$23.88 |
$346,149 |
D/D |
(14,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-03-27 |
4 |
AS |
$18.22 |
$59,302 |
D/D |
(3,250) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-03-27 |
4 |
OE |
$2.48 |
$8,060 |
D/D |
3,250 |
3,250 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-27 |
4 |
AS |
$16.97 |
$55,163 |
D/D |
(3,250) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-27 |
4 |
OE |
$2.48 |
$8,060 |
D/D |
3,250 |
3,250 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-29 |
4 |
AS |
$15.81 |
$51,388 |
D/D |
(3,250) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-29 |
4 |
OE |
$2.48 |
$8,060 |
D/D |
3,250 |
3,250 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2024-01-02 |
4 |
AS |
$15.01 |
$140,839 |
D/D |
(9,383) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2024-01-02 |
4 |
OE |
$2.48 |
$23,270 |
D/D |
9,383 |
9,383 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2023-12-29 |
4 |
AS |
$15.00 |
$300 |
D/D |
(20) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2023-12-29 |
4 |
OE |
$2.48 |
$50 |
D/D |
20 |
20 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2023-12-28 |
4 |
OE |
$2.48 |
$6,118 |
D/D |
2,467 |
2,467 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2023-12-28 |
4 |
AS |
$15.07 |
$37,188 |
D/D |
(2,467) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2023-12-26 |
4 |
AS |
$15.00 |
$1,500 |
D/D |
(100) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2023-12-26 |
4 |
OE |
$2.48 |
$248 |
D/D |
100 |
100 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2023-12-22 |
4 |
AS |
$15.07 |
$15,525 |
D/D |
(1,030) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Financial Officer |
• – – |
2023-12-22 |
4 |
OE |
$2.48 |
$2,554 |
D/D |
1,030 |
1,030 |
0 |
- |
|
22 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
